<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5884">
  <stage>Registered</stage>
  <submitdate>16/05/2016</submitdate>
  <approvaldate>16/05/2016</approvaldate>
  <nctid>NCT02777008</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects</studytitle>
    <scientifictitle>A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP543.1001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CTP-543
Treatment: drugs - Placebo for CTP-543

Experimental: CTP-543 Single Dose - Single oral dose

Experimental: CTP-543 Multiple Dose - Multiple oral dose for 7 consecutive days


Treatment: drugs: CTP-543


Treatment: drugs: Placebo for CTP-543


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome>
      <timepoint>24 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Measurement of CTP-543 exposure in plasma under fasted conditions</outcome>
      <timepoint>24 hours</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy adult males and females between 18 and 50 years of age, inclusive

          -  Body weight = 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of clinically significant central nervous system (eg, seizures), cardiac,
             pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions

          -  PR interval &gt; 220 msec or QRS duration &gt; 120 msec or QTcF interval &gt; 450 msec obtained
             at screening visit or prior to the first dose of study drug

          -  History of herpes zoster

          -  Hemoglobin, white blood cell, or platelet levels below the lower reference limit at
             screening or prior to the first dose of study drug

          -  Liver function tests greater than the upper limit of normal

          -  Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
             virus surface antigen, or hepatitis C virus antibody

          -  Urinalysis positive for protein or glucose

          -  A positive screen for alcohol, drugs of abuse, or tobacco use

          -  Donation of blood, plasma or other blood products prior to screening

          -  A positive tuberculosis test</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>77</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital> - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Concert Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Single- and multiple-ascending dose study of CTP-543 in healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02777008</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Colleen Hamilton</name>
      <address>Concert Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>